Abstract
Nonalcoholic fatty liver disease (NAFLD) is recognized as a metabolic disease characterized by hepatic steatosis. Despite the growing burden of NAFLD, approved pharmacological treatment is lacking. As an inhibitor of androgen receptor (AR), EPI-001 is being explored for the treatment of prostate cancer. This study aimed to investigate the potential of EPI-001 for treating NAFLD in free fatty acids (FFAs)-induced human hepatic cells and high-fat-high-sugar (HFHS)-feeding mice. Our results showed that EPI-001 reduced lipid accumulation in hepatic cells and ameliorated hepatic steatosis in mouse livers. Further exploration suggested that the effect of EPI-001 was associated with CYP2E1-mediated reduction of reactive oxygen species (ROS). This provides encouraging evidence for further studies on EPI-001 therapy for NAFLD.
Original language | English |
---|---|
Article number | 16063 |
Journal | International Journal of Molecular Sciences |
Volume | 23 |
Issue number | 24 |
DOIs | |
Publication status | Published - 16 Dec 2022 |
Bibliographical note
Funding Information:This work was supported by the National Natural Science Foundation of China (No. 81972281), and Natural Science Foundation of Zhejiang Province (No. LGF22C010005).
Publisher Copyright:
© 2022 by the authors.